GMPharma Consult ApS: Financial statements 2024
CVR: 42760137
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
GMPharma Consult ApS (CVR 42760137) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -34,520 and a net result of DKK -39,429 compared with DKK -12,843 the year before. Equity in the 2024 report amounted to DKK 88,235. The solvency ratio was 74.2%.
- Gross Profit
- DKK -34,520
- Profit/Loss
- DKK -39,429
- Equity
- DKK 88,235
- Total Assets
- DKK 118,985
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -35 t. | -39 t. | 88 t. | 0 |
| 2023 | 0 | -14 t. | -13 t. | 128 t. | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
GMPharma Consult ApS has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -12,843.
As of November 13, 2024, Ina Maria Carolina Glamheden-Helle is registered as director of GMPharma Consult ApS.
As of November 13, 2024, Esben Joakim de Meza Skjernov has stepped down as liquidator of GMPharma Consult ApS.
On November 13, 2024, GMPharma Consult ApS exited liquidation.
As of October 2, 2024, Esben Joakim de Meza Skjernov is registered as liquidator of GMPharma Consult ApS.
On October 2, 2024, GMPharma Consult ApS entered liquidation.
As of August 22, 2024, Ina Glamheden-Helle has stepped down as director of GMPharma Consult ApS.
About GMPharma Consult ApS
GMPharma Consult ApS is a Danish company of the type Anpartsselskab based in Hillerød, founded in 2021. The company is registered under the industry Anden teknisk rådgivning. The management consists of Ina Maria Carolina Glamheden-Helle. The company is owned by Startplattan 192299 Aktiebolag. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -11,057 and a net result of DKK -29,176 compared with DKK -39,429 the year before. Equity in the 2025 report amounted to DKK 59,058.